NCT00365209View on ClinicalTrials.gov

Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

January 31, 2011

Conditions
Healthy, no Evidence of DiseaseTobacco Use Disorder
Interventions
OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

DRUG

curcumin

Given orally

Trial Locations (1)

92868

Chao Family Comprehensive Cancer Center, Orange

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00365209 - Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci) | Biotech Hunter | Biotech Hunter